171 related articles for article (PubMed ID: 24030275)
1. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells.
Cázares-Marinero Jde J; Top S; Vessières A; Jaouen G
Dalton Trans; 2014 Jan; 43(2):817-30. PubMed ID: 24153445
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
4. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.
Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS
Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362
[TBL] [Abstract][Full Text] [Related]
7. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
8. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
Palermo AF; Diennet M; El Ezzy M; Williams BM; Cotnoir-White D; Mader S; Gleason JL
Bioorg Med Chem; 2018 Aug; 26(15):4428-4440. PubMed ID: 30078609
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals.
Wu S; Luo Z; Yu PJ; Xie H; He YW
Biol Chem; 2016 Jan; 397(1):75-83. PubMed ID: 26431101
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells.
Xie R; Shi J; Qu Y; Tang P; Wu X; Yang M; Yuan Q
Med Chem; 2015; 11(7):636-48. PubMed ID: 25922175
[TBL] [Abstract][Full Text] [Related]
13. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.
Mekala JR; Ramalingam PS; Mathavan S; Yamajala RBRD; Moparthi NR; Kurappalli RK; Manyam RR
Chem Biol Interact; 2022 Apr; 357():109876. PubMed ID: 35283086
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
19. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
